Shots:

• Aduro to receive $12M upfront- up to $620M milestones and royalties on sales from Lilly. Lilly to get rights for Aduro’s cGAS-STING pathway inhibitor program and will be responsible for all costs for its global commercialization
• Lilly to fund the research program- Aduro will be responsible for the research of molecules in cGAS-STING Pathway Inhibitor Program with an option to co-fund- leading to increment in royalties
• Aduro's cGAS-STING Pathway Inhibitor program is planned to assess inhibition of intracellular stimulator of interferon genes (STING) pathway- that leads to reduction in immune response in autoimmune diseases

Ref: Eli Lilly | Image: Eli Lilly